Variability in the response to antiplatelet treatment in diabetes mellitus

Prostaglandins and Other Lipid Mediators

Volumn 98, Issue 3-4, 2012, Pages 48-55

  Davì, Giovanni ^a   Vazzana, Natale ^a   Sestili, Simona ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Aspirin; Atherothrombosis; Diabetes mellitus; Oxidative stress; Platelet activation; Primary prevention; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 1; IBUPROFEN; NAPROXEN; PRASUGREL; THROMBOXANE; TICAGRELOR;

ACUTE CORONARY SYNDROME; DIABETES MELLITUS; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATALITY; HUMAN; LOW DRUG DOSE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; THROMBOXANES; TREATMENT OUTCOME;

EID: 84863482006     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2012.01.008     Document Type: Review

References (95)

1. B. Stratmann, and D. Tschoepe Atherogenesis and atherothrombosis - focus on diabetes mellitus Best Pract Res Clin Endocrinol Metab 23 2009 291 303
2. T.F. Luscher, M.A. Creager, J.A. Beckman, and F. Cosentino Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy Circulation 108 2003 1655 1661
3. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
4. J.A. Beckman, M. Creager, and P. Libby Diabetes and atherosclerosis: epidemiology, pathophysiology, and management J Am Med Assoc 287 2002 2570 2581
5. E.J. Boyko, and J.B. Meigs Does diabetes always confer coronary heart disease risk equivalent to a prior myocardial infarction?: implications for prevention Diabetes Care 34 2011 782 784
6. M. Laakso Hyperglycemia and cardiovascular disease in type 2 diabetes Diabetes 48 1999 937 942
7. M.E. Cooper, F. Bonnet, M. Oldfield, and K. Jandeleit-Dahm Mechanisms of diabetic vasculopathy: an overview Am J Hypertens 14 2001 475 486
8. T. Nishikawa, D.X.L. Du Edelstein, and S. Yamagishi Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404 2000 787 790
9. G.M. Pieper, and H. Riazul Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C J Cardiovasc Pharmacol 30 1997 528 532
10. K.K. Yerneni, W. Bai, B.V. Khan, R.M. Medford, and R. Natarajan Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells Diabetes 48 1999 855 864
11. P. Ferroni, S. Basili, A. Falco, and G. Davì Platelet activation in type 2 diabetes mellitus J Thromb Haemost 2 2004 1282 1291
12. R. Ross Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115 126
13. G. Davì, P. Gresele, and F. Violi Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease Circulation 96 1997 69 75
14. G. Davì, F. Chiarelli, and F. Santilli Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration Circulation 107 2003 3199 3203
15. F. Santilli, G. Formoso, and P. Sbraccia Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus J Thromb Haemost 8 2010 828 837
16. P. Gresele, G. Guglielmini, and M. De Angelis Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus J Am Coll Cardiol 41 2003 1013 1020
17. G. Davì, G. Ciabattoni, and A. Consoli In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation Circulation 99 1999 224 229
18. G. Davì, I. Catalano, and M. Averna Thromboxane biosynthesis and platelet function in type II diabetes mellitus N Engl J Med 322 1990 1769 1774
19. F. Santilli, G. Davì, and A. Consoli Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus J Am Coll Cardiol 47 2006 391 397
20. R. De Cristofaro, B. Rocca, and E. Vitacolonna Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus J Thromb Haemost 1 2003 250 256
21. C. Falcon, G. Pfliegler, H. Deckmyn, and J. Vermylen The platelet insulin receptor: detection, partial characterization, and search for a function Biochem Biophys Res Commun 157 1988 1190 1196
22. V. Randriamboavonjy, and I. Fleming Insulin, insulin resistance, and platelet signaling in diabetes Diabetes Care 32 2009 528 530
23. J.L. Ferreiro, J.A. Gómez-Hospital, and D.J. Angiolillo Platelet abnormalities in diabetes mellitus Diab Vasc Dis Res 7 2010 251 259
24. G. Davì, M.T. Guagnano, and A. Ciabattoni Platelet activation in obese women: role of inflammation and oxidant stress JAMA 288 2002 2008 2014
25. S. Basili, G. Pacini, and M.T. Guagnano Insulin resistance as a determinant of platelet activation in obese women J Am Coll Cardiol 48 2006 2531 2538
26. M. Trovati, E.M. Mularoni, and S. Burzacca Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients Diabetes 44 1995 1318 1322
27. American Diabetes Association Standards of medical care in diabetes - 2011 Diabetes Care 34 January (Suppl 1) 2011 S11 S61
28. C. Patrono, and Rocca B. Aspirin 110 years later J Thromb Haemost 7 Suppl 1 2009 258 261
29. C. Patrono, L.A. García Rodríguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2005 2373 2383
30. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
31. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
32. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART, Primary Care Cardiovascular Society, UK, and Stroke Association JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart 91 Suppl 5 2005 v1 v52
33. S.C. Smith Jr., J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372
34. P.K. Kuchulakanti, W.W. Chu, and R. Torguson Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents Circulation 113 2006 1108 1113
35. I. Iakovou, T. Schmidt, and E. Bonizzoni Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
36. P. Urban, A.H. Gershlick, and G. Guagliumi Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry Circulation 113 2006 1434 1441
37. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 116 2007 e148 e304
38. E.M. Antman, D.T. Anbe, and P.W. Armstrong ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction) Circulation 110 2004 e82 e292
39. S.B. King 3rd, S.C. Smith Jr, J.W. Hirshfeld Jr, A.K. Jacobs, D.A. Morrison, and D.O. Williams 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee Circulation 117 2008 261 295
40. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment Diabetes 54 2005 2430 2435
41. T. Geisler, N. Anders, and M. Paterok Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation Diabetes Care 30 2007 372 374
42. V. Serebruany, I. Pokov, W. Kuliczkowski, J. Chesebro, and J. Badimon Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease Thromb Haemost 100 2008 76 82
43. D.J. Angiolillo, E. Bernardo, and C. Ramírez Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment J Am Coll Cardiol 48 2006 298 304
44. S.D. Wiviott, E. Braunwald, and D.J. Angiolillo TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636
45. D.J. Angiolillo, J.J. Badimon, and J.F. Saucedo A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-3 trial Eur Heart J 32 2011 838 846
46. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
47. T.K. Schramm, G.H. Gislason, and L. Kober Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people Circulation 117 2008 1945 1954
48. U. Bulugahapitiya, S. Siyambalapitiya, J. Sithole, and I. Idris Is diabetes a coronary risk equivalent? Systematic review and meta-analysis Diabet Med 26 2009 142 148
49. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
50. Z.T. Bloomgarden Diabetes and cardiovascular disease Diabetes Care 34 2011 e24 e30
51. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 diabetes: recommendations for standard, comprehensive, and minimal care Diabet Med 23 2006 579 593
52. L. Rydén, E. Standl, and M. Bartnik Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 2007 88 136
53. H.W. Rodbard, L. Blonde, and S.S. Braithwaite AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus Endocr Pract 13 Suppl 1 2007 1 68
54. O.K. Bhattacharyya, B.R. Shah, and G.L. Booth Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines CMAJ 179 2008 920 926
55. M. Pignone, M.J. Alberts, and J.A. Colwell Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation Circulation 121 2010 2694 2701
56. M. Pignone, and C.D. Williams Aspirin for primary prevention of cardiovascular disease in diabetes mellitus Nat Rev Endocrinol 6 2010 619 628
57. C. Patrono Aspirin as an antiplatelet drug N Engl J Med 330 1994 1287 1294
58. L. Swaim, and R.S. Hillman Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study J Thromb Thrombolysis 28 2009 94 100
59. P.M. Ridker, N.R. Cook, and I.M. Lee A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women N Engl J Med 352 2005 1293 1304
60. F. Santilli, B. Rocca, and R. De Cristofaro Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin resistance J Am Coll Cardiol 53 2009 667 677
61. ETDRS Investigators Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14 JAMA 268 1992 1292 1300
62. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study N Engl J Med 321 1989 1825 1828
63. Antithrombotic Trialists' (ATT) Collaboration, C. Baigent, and L. Blackwell Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
64. J. Belch, A. MacCuish, I. Campbell, and S. Cobbe The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 2008 a1840
65. H. Ogawa, M. Nakayama, and T. Morimoto Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2008 2134 2141
66. G. De Berardis, M. Sacco, and G.F. Strippoli Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials BMJ 339 2009 b4531
67. Collaborative Group of the Primary Prevention Project Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice Lancet 351 1998 1755 1762
68. D.L. Bhatt, K.A. Fox, and W. Hacke Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
69. B. Rocca, and C. Patrono Determinants of the interindividual variability in response to antiplatelet drugs J Thromb Haemost 3 2005 1597 1602
70. C. Patrono, B. Coller, G.A. FitzGerald, J. Hirsh, and G. Roth Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 234S 264S
71. F. Catella-Lawson, M.P. Reilly, and S.C. Kapoor Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 2001 1809 1817
72. M.L. Capone, M.G. Sciulli, and S. Tacconelli Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects J Am Coll Cardiol 45 2005 1295 1301
73. M.K. Halushka, L.P. Walker, and P.V. Halushka Genetic variation in cyclooxygenase 1: effects on response to aspirin Clin Pharmacol Ther 73 2003 122 130
74. C. Pettinella, M. Romano, L. Stuppia, F. Santilli, R. Liani, and G. Davì Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin Thromb Haemost 101 2009 687 690
75. G. Davì, and C. Patrono Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
76. A. Dragani, S. Pascale, and A. Recchiuti The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy Blood 115 2010 1054 1061
77. C. Patrono, A. Falco, and G. Davì Isoprostane formation and inhibition in atherothrombosis Curr Opin Pharmacol 5 2005 198 203
78. F. Santilli, L. Mucci, and G. Davi TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus Intern Emerg Med 6 2011 203 212
79. A. Giustina, P. Perini, and P. Desenzani Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients Diabetes 47 1998 423 430
80. C. Watala, J. Pluta, and J. Golanski Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin J Mol Med 83 2005 148 158
81. F.M. Pulcinelli, L.M. Biasucci, and S. Riondino COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment Eur Heart J 30 2009 1279 1286
82. J. DiChiara, K.P. Bliden, and U.S. Tantry The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 56 2007 3014 3019
83. V. Evangelista, G. de Berardis, and L. Totani Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin J Thromb Haemost 5 2007 2197 2203
84. J.W. Eikelboom, J. Hirsh, J.I. Weitz, M. Johnston, Q. Yi, and S. Yusuf Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 2002 1650 1655
85. M. Vaduganathan, C.L. Alviar, and M.E. Arikan Platelet reactivity and response to aspirin in subjects with the metabolic syndrome Am Heart J 156 2008 e1 e7
86. C. Watala, M. Boncler, T. Pietrucha, and Z. Trojanowski Possible mechanisms of the altered platelet volume distribution in type 2 diabetes: does increased platelet activation contribute to platelet size heterogeneity? Platelets 10 1999 52 60
87. S. Guthikonda, E.I. Lev, and R. Patel Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin J Thromb Haemost 5 2007 490 496
88. G. Spectre, L. Arnetz, C.G. Östenson, K. Brismar, N. Li, and P. Hjemdahl Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications Thromb Haemost 106 2011 491 499
89. P.M. Bath, and R.J. Butterworth Platelet size: measurement, physiology and vascular disease Blood Coagul Fibrinolysis 7 1996 157 161
90. L. Vizioli, S. Muscari, and A. Muscari The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases Int J Clin Pract 63 2009 1509 1515
91. Z. Hekimsoy, B. Payzin, T. Ornek, and G. Kandogan Mean platelet volume in type 2 diabetic patients J Diabetes Complications 18 2004 173 176
92. B. Rocca, P. Secchiero, and G. Ciabattoni Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets Proc Natl Acad Sci U S A 99 2002 7634 7639
93. S. Guthikonda, C.L. Alviar, and M. Vaduganathan Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease J Am Coll Cardiol 52 2008 743 749
94. B. Rocca, F. Santilli, and D. Pitocco Abstract 12233: variability in the recovery rate of platelet cyclooxygenase activity during chronic therapy with low-dose aspirin in type 2 diabetes Circulation 122 2010 A12233
95. F.G. Fowkes, J.F. Price, M.C. Stewart, I. Butcher, G.C. Leng, and A.C. Pell Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial JAMA 303 2010 841 848